|
|
|
市場調查報告書
全球的處方箋非專利藥品市場（第 5 版）
The World Market for Prescription Generic Drugs, 5th Edition
|
全球的處方箋非專利藥品市場（第 5 版） 是由出版商Kalorama Information在2006年04月所出版的。
這份英文市場調查報告書包含310 pages 價格從美金3500起跳。
非專利藥品企業的展望逐漸轉變，在製藥產業中相對勢力增強的同時，提供產品線的廣度與深度也在逐漸增加當中。如此強健的成長趨勢，不僅來自積極策略及臨床和一般消費人口的接受度提高，也源於過去幾年內知名藥品的專利到期失效的關係。
專門從事製藥、生物科技、醫療儀器等眾多生命科學市場調查的調查公司 Kalorama Information （總公司：紐約州），針對全球的一般處方箋藥品市場進行調查分析，並出版最新的調查報告書 "The Worldwide Market for Prescription Generic Drugs, 5th Edition" 。
本報告書內容包括：全球處方箋非專利藥品市場中主要競爭企業的市場規模、成長、佔有率分析，以及相關法規限制、臨床事業趨勢、問題等。內容綱要摘記如下：
第1章 實施概要
- 簡介
- 調查範圍與方法論
- 市場規模與成長
- 影響市場的趨勢
- 市場展望
第2章 概述
第3章 過敏／呼吸器官用藥
第4章 止痛藥、非類固醇類消炎藥、治療風濕病藥
第5章 麻醉藥
第6章 防止感染藥
第7章 抗癌劑
第8章 心血管藥
第9章 中樞神經系統／精神病治療藥
第10章 胃腸藥
第11章 荷爾蒙
第12章 眼藥
第13章 全球市場摘要
第14章 問題與趨勢
- Hatch-Waxman 法之說明與其缺點
- FDA、資金調度、審查次數
- 大型藥商的策略：防守與攻擊
- 經許可的非專利藥品
- 生物非專利藥品
- 醫療輔助計劃的非專利藥品補償問題
- 高齡人口
- 非專利藥品名稱的混淆
- 擴大非專利藥品範圍
- 國際性非專利藥品的問題
- 產業整合
- 新的非專利藥品大企業
- 專利問題：申請與課題
- 專利改革
- 非專利藥品的成長：處方、許可、影響
- 倒數計時的非專利藥品施德丁（ Statins ）
- 處方箋藥的成本
- 處方箋藥提高相容性
- 非專利藥取樣
第15章 企業資料
附錄：企業指南
Abstract
The landscape of generic companies is changing: their relative might in the
industry is increasing and the product lines their offering are growing in
depth and breadth. Strong growth in the sector has come not only from more
aggressive tactics and better acceptance in the clinical and consumer
population, but by the loss of patent protection in the past few years of some
huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox,
Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol.
This comprehensive study quantifies world markets 2000 to 2010 in the
following therapeutic categories: examined at the level of manufacturers'
revenues in each of the following product categories:
- allergy and respiratory drugs,
- analgesics (including NSAIDs) and anti-rheumatic drugs,
- anesthesia,
- anti-infectives,
- cancer drugs,
- cardiovascular drugs,
- CNS drugs,
- gastrointestinal drugs,
- hormone drugs, and
- ophthalmic drugs.
In addition to market size and growth, market share of leading competitors,
the report discusses regulatory, clinical, and business trends and issues in
detail, including
- how the Hatch-Waxman Act works and fails to work,
- how FDA funding plans will affect filings and approvals in the coming
years,
- what strategies big pharma is using to fend off market share erosion,
like autorized generics and aggressive patent filing,
- how generic biologics fit in the picture,
- how M&A activity is changing the landscape, and
- many more
The report also details the big-name drugs set to lose protection over the
next 6 years and what level of revenue is at stake for whom.
The report also includes profiles of the top players, including:
- Actavis Group
- Altana Pharma AG
- Andrx Corporation
- Apotex Group
- Aurobindo Pharma, Ltd.
- Barr Laboratories, Inc.
- Bedford Laboratories
- Lannett Company, Inc.
- Mylan Laboratories, Inc.
- Orchid Chemicals and Pharmaceuticals, Ltd.
- Par Pharmaceuticals, Inc.
- Perrigo Company
- PLIVA Pharmaceuticals, Inc.
- Ranbaxy Laboratories, Ltd.
- Roxane Laboratories, Inc.
- Sandoz International, GmbH
- Taro Pharmaceutical Industries Ltd.
- TEVA Pharmaceutical Industries, Ltd.
- Watson Pharmaceuticals, Inc.
- United Research Laboratories and Mutual Pharmaceutical Company
- Zydus Pharmaceuticals, Inc.
Table of Contents
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Trends Affecting the Market
- Market Outlook
Chapter Two: Introduction
- Industry Development
- Generic Drug Industry Evolution
- FDA Regulation
- Development and Approval Process
- Industry Structure
- Product Distribution
- Patent Expirations
Chapter Three: Allergy and Respiratory Drugs
- Product Categories
- Asthma, Bronchodilators and Corticosteroids
- Inhaled Corticosteroids
- Antiasthmatic Agents
- Bronchodilating Agents
- Antihistamines, Decongestants, and Cough Preparations
- Antihistamines
- Decongestants
- Cough Preparations
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Four: Analgesics, Nonsteroidal Anti-Inflammatory Drugs, and Antirheumatic Drugs
- Product Categories
- Analgesics
- Nonsteroidal Anti-inflammatory Drugs
- Antirheumatics
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter five: Anesthesia Drugs
- Product Categories
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Six: Anti-Infectives
- Product Categories
- Systemic Anti-Infectives
- Topical Anti-Infectives
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter seven: Cancer Drugs
- Products
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Eight: Cardiovascular Drugs
- Product Categories
- Positive Inotropic Agents
- Antiadrenergics
- Beta-Adrenergic Blocking Agents
- Vasodilators
- Calcium Channel Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Antiarrhythmics
- Antihyperlipidemic Agents
- Anticoagulants
- Diuretics
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs. World Market
- Competitive Analysis
Chapter Nine: Central Nervous System and Psychotherapeutic Drugs
- Product Categories
- Antidepressants, Stimulants, and Antipsychotics
- Antidepressants
- Stimulants
- Antipsychotics
- Anticonvulsants, Antispasmodics, and Muscle Relaxants
- Anticonvulsants
- Antispasmodics
- Muscle Relaxants
- Parkinsons Disease, Myasthenia Gravis, and Multiple Sclerosis
- Parkinsons Disease
- Myasthenia Gravis
- Multiple Sclerosis
- Sedatives, Hypnotics, and Antianxiety Drugs
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Ten: Gastrointestinal Drugs
- Product Categories
- Antidiarrheals
- Antinauseants
- Antispasmodics
- Antiulcer
- Digestants
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs the World Market
- Competitive Analysis
Chapter Eleven: Hormonal Drugs
- Product Categories
- Male and Female Hormones
- Corticosteroids
- Diabetes Drugs
- Thyroid Drugs
- Product News
- Market Size and Forecast
- The World Market
- U.S. vs World Market
- Competitive Analysis
Chapter Twelve: Ophthalmic Drugs
- Product Categories
- Ophthalmic Anti-Infectives
- Ophthalmic Anti-Inflammatories and Mast Cell Inhibitors
- Glaucoma Agents
- Product News
- Market Size and Forecast
- The World Market
- U.S. vs World Market
- Competitive Analysis
Chapter Thirteen: World Market Summary
- Overview
- Total Market Size and Forecast
- Market and Competitive Analysis
Chapter Fourteen: Issues and Trends
- Understanding Hatch-Waxman and Its Shortfalls
- The FDA, Funding and Review Times
- Big Pharma Tactics Defensive and Offensive
- Authorized Generics
- Generic Biologics
- Medicaid Generic Drug Reimbursement Issues
- The Elderly
- Confusion in Generic Drug Names
- Broadening Generic Horizons
- International Generic Drug Issues
- Industry Consolidation
- New Generic Giants
- Patent Issues: Filings and Challenges
- Patent Reform
- Generic Growth: Prescriptions, Approvals, Impact
- Generic Statins Countdown
- Prescription Drug Costs
- Generics Improve Compliance
- Generic Drug Sampling
Chapter Fifteen: Company Profiles
- Industry Structure and Participants
- Actavis Group
- Altana Pharma AG
- Andrx Corporation
- Apotex Group
- Aurobindo Pharma, Ltd
- Barr Laboratories, Inc.
- Bedford Laboratories
- Lannett Company, Inc.
- Mylan Laboratories, Inc.
- Orchid Chemicals and Pharmaceuticals, Ltd.
- Par Pharmaceuticals, Inc.
- Perrigo Company
- PLIVA Pharmaceuticals, Inc.
- Ranbaxy Laboratories, Ltd.
- Roxane Laboratories, Inc.
- Sandoz International, GmbH
- Taro Pharmaceutical Industries Ltd.
- TEVA Pharmaceutical Industries, Ltd.
- Watson Pharmaceuticals, Inc.
- United Research Laboratories and Mutual Pharmaceutical Company
- Zydus Pharmaceuticals, Inc
Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Market Suumary: World Market for Prescription Generic Drugs
Revenues by Segment 2000-2010
- Figure 1-1: Market Summary: Trending in the World Market for
Prescription Generic Drugs by Segment 2000-2010
Chapter Two: Introduction
- Figure 2-1: Abbreviated New Drug Application Review Flow Chart
- Table 2-1: Brand Name Companies with Generic Subsidiaries
- Table 2-2: Number of Best Selling Drugs with Patents Expiring in Years
2006-2012 Grouped by Treatment Category
- Table 2-3: Best Selling Prescription Drugs with Expected Patent
Expirations (Year of Expiration, Brand, Manufacturer, Indication, 2004
Revenues) 2006-2012
Chapter Three: Allergy and Respiratory Drugs
- Table 3-1: Prescription Allergy and Respiratory ANDA Approvals, 2005
- Table 3-2: The World Market for Prescription Generic Allergy and
Respiratory Drugs by Type 2000-2010
- Figure 3-1: The World Market for Prescription Generic Allergy and
Respiratory Drugs, Revenues by Type 2000-2010
- Table 3-3: The World Market for Prescription Generic Allergy and
Respiratory Drugs, Market Share by Type 2000-2010
- Table 3-4: The World Market for Prescription Generic Allergy and
Respiratory Drugs, U.S. Revenues and Share 2000-2010
- Figure 3-2: The World Market for Prescription Generic Allergy and
Respiratory Drugs, Displaying U.S. Revenues 2000-2010
- Table 3-5: The World Market for Prescription Generic Allergy and
Respiratory Drugs, Revenues and Market Share by Supplier 2005
- Figure 3-3: The World Market for Prescription Generic Allergy and
Respiratory Drugs, Market Share by Leading Supplier 2005
Chapter Four: Analgesics, Nonsteroidal Anti-Inflammatory Drugs, and
Antirheumatic Drugs
- Table 4-1: Prescription Generic Analgesic, NSAID, and Antirheumatic ANDA
Approvals, 2005
- Table 4-2: The World Market for Prescription Generic Analgesics, NSAIDs
and Antirheumatic Drugs by Type 2000-2010
- Figure 4-1: The World Market for Prescription Generic Analgesics,
NSAIDs, and Antirheumatic Drugs, Revenues by Type 2000-2010
- Table 4-3: The World Market for Prescription Generic Analgesics, NSAIDs,
and Antirheumatic Drugs, Market Share by Type 2000-2010
- Table 4-4: The World Market for Prescription Generic Analgesics, NSAIDs,
and Antirheumatic Drugs, U.S. Revenues and Share 2000-2010
- Figure 4-2: The World Market for Prescription Generic Analgesics,
NSAIDs, and Antirheumatic Drugs Displaying U.S. Revenues 2000-2010
- Table 4-5: The World Market for Prescription Generic Analgesics, NSAIDs,
and Antirheumatic Drugs Revenues and Market Share by Supplier 2005
- Figure 4-3: The World Market for Prescription Generic Analgesics,
NSAIDs, and Antirheumatic Drugs Market Share by Leading Supplier 2005
Chapter Five: Anesthesia Drugs
- Table 5-1: Prescription Generic Anesthesia Drug ANDA Approvals, 2005
- Table 5-2: The World Market for Prescription Generic Anesthesia Drugs
2000-2010
- Figure 5-1: The World Market for Prescription Generic Anesthesia Drugs
Revenues 2000-2010
- Table 5-3: The World Market for Prescription Generic Anesthesia Drugs,
U.S. Revenues and Share 2000-2010
- Figure 5-2: The World Market for Prescription Generic Anesthesia Drugs
Displaying U.S. Revenues 2000-2010
- Table 5-4: The World Market for Prescription Generic Anesthesia Drugs,
Revenues and Market Share by Supplier 2005
- Figure 5-3: The World Market for Prescription Generic Anesthesia Drugs
Market Share by Leading Supplier 2005
CHAPTER Six: Anti-Infectives
- Table 6-1: Prescription Generic Anti-infective Drug ANDA Approvals, 2005
- Table 6-2: The World Market for Prescription Generic Anti-Infective
Drugs by Type 2000-2010
- Figure 6-1: The World Market for Prescription Generic Anti-Infective
Drugs, Revenues by Type 2000-2010
- Table 6-3: The World Market for Prescription Generic Anti-Infective
Drugs, Market Share by Type 2000-2010
- Table 6-4: The World Market for Prescription Generic Anti-Infective
Drugs U.S. Revenues and Share 2000-2010
- Figure 6-2: The World Market for Prescription Generic Anti-Infective
Drugs Displaying U.S. Revenues 2000-2010
- Table 6-5: The World Market for Prescription Generic Anti-Infective
Drugs, Revenues and Market Share by Supplier 2005
- Figure 6-3: The World Market for Prescription Generic Anti-Infective
Drugs Market Share by Leading Supplier 2005
Chapter Seven: Cancer Drugs
- Table 7-1: Prescription Generic Cancer Drug ANDA Approvals 2005
- Table 7-2: The World Market for Prescription Generic Cancer Drugs
2000-2010
- Figure 7-1: The World Market for Prescription Generic Cancer Drugs
Revenues 2000-2010
- Table 7-3: The World Market for Prescription Generic Cancer Drugs, U.S.
Revenues and Share 2000-2010
- Figure 7-2: The World Market for Prescription Generic Cancer Drugs
Displaying U.S. Revenues 2000-2010
- Table 7-4: The World Market for Prescription Generic Cancer Drugs,
Revenues and Market Share by Supplier 2005
- Figure 7-3: The World Market for Prescription Generic Cancer Drugs
Market Share by Leading Supplier 2005
Chapter Eight: Cardiovascular Drugs
- Table 8-1: Prescription Generic Cardiovascular Drug ANDA
- Approvals. 2005
- Table 8-2: The World Market for Prescription Generic Cardiovascular
Drugs by Type 2000-2010
- Figure 8-1: The World Market for Prescription Generic Cardiovascular
Drugs Revenues by Type 2000-2010
- Table 8-3: The World Market for Prescription Generic Cardiovascular
Drugs, Market Share by Type 2000-2010
- Figure 8-2: The World Market for Prescription Generic Cardiovascular
Drugs, Share by Type 2005 and 2010
- Table 8-4: The World Market for Prescription Generic Cardiovascular
Drugs U.S. Revenues and Share 2000-2010
- Figure 8-3: The World Market for Prescription Generic Cardiovascular
Drugs Displaying U.S. Revenues 2000-2010
- Table 8-5: The World Market for Prescription Generic Cardiovascular
Drugs, Revenues and Market Share by Supplier 2005
- Figure 8-4: The World Market for Prescription Generic Cardiovascular
Drugs, Market Share by Leading Supplier 2001
Chapter Nine: Central Nervous System and Psychotherapeutic Drugs
- Table 9-1: Prescription Generic Central Nervous System/Psychotherapeutic
Drug ANDA Approvals 2005
- Table 9-2: The World Market for Prescription Generic Central Nervous
System Drugs by Type 2000-2010
- Figure 9-1: The World Market for Prescription Generic Central Nervous
System Drugs Revenues by Type 2000-2010
- Table 9-3: The World Market for Prescription Generic Central Nervous
System Drugs, Market Share by Type 2000-2010
- Table 9-4: The World Market for Prescription Generic Central Nervous
System Drugs, U.S. Revenues and Share 2000-2010
- Figure 9-2: The World Market for Prescription Generic Central Nervous
System Drugs Displaying U.S. Revenues 2000-2010
- Table 9-5: The World Market for Prescription Generic Central Nervous
System Drugs, Revenues and Market Share by Supplier 2005
- Figure 9-3: The World Market for Prescription Generic Central Nervous
System Drugs, Market Share by Leading Supplier 2005
Chapter Ten: Gastrointestinal Drugs
- Table 10-1: Prescription Generic Gastrointestinal Drug ANDA Approvals 2005
- Table 10-2: The World Market for Prescription Generic Gastrointestinal
Drugs by Type, 2000-2010
- Figure 10-1: The World Market for Prescription Generic Gastrointestinal
Drugs Revenues by Type 2000-2010
- Table 10-3: The World Market for Prescription Generic Gastrointestinal
Drugs, Market Share by Type 2000-2010
- Figure 10-2: The World Market for Prescription Generic Gastrointestinal
Drugs, Share by Type 2005 and 2010
- Table 10-4: The World Market for Prescription Generic Gastrointestinal
Drugs, U.S. Revenues and Share 2000-2010
- Figure 10-3: The World Market for Prescription Generic Gastrointestinal
Drugs, Displaying U.S. Revenues 2000-2010
- Table 10-5: The World Market for Prescription Generic Gastrointestinal
Drugs, Revenues and Market Share by Supplier2005
- Figure 10-4: The World Market for Prescription Generic Gastrointestinal
Drugs, Market Share by Leading Supplier 2005
Chapter Eleven: Hormonal Drugs
- Table 11-1: Prescription Generic Hormone Drug ANDA Approvals 2005
- Table 11-2: The World Market for Prescription Generic Hormone Drugs by
Type 2000-2010
- Figure 11-1: The World Market for Prescription Generic Hormone Drugs
Revenues by Type 2000-2010
- Table 11-3: The World Market for Prescription Generic Hormone Drugs,
Market Share by Type 2000-2010
- Figure 11-2: The World Market for Prescription Generic Hormone Drugs
Share by Type 2005 and 2010
- Table 11-4: The World Market for Prescription Generic Hormone Drugs U.S.
Revenues and Share 2000-2010
- Figure 11-3: The World Market for Prescription Generic Hormone Drugs
Displaying U.S. Revenues 2000-2010
- Table 11-5: The World Market for Prescription Generic Hormone Drugs,
Revenues and Market Share by Supplier 2005
- Figure 11-4: The World Market for Prescription Generic Hormone Drugs
Market Share by Leading Supplier 2005
Chapter Twelve: Ophthalmic Drugs
- Table 12-1: Prescription Generic Ophthalmic Drug ANDA Approvals 2001
- Table 12-2: The World Market for Prescription Generic Ophthalmic Drugs
by Type 2000-2010
- Figure 12-1: The World Market for Prescription Generic Ophthalmic Drugs
Revenues by Type 2000-2010
- Table 12-3: The World Market for Prescription Generic Ophthalmic Drugs,
Market Share by Type 2000-2010
- Table 12-4: The World Market for Prescription Generic Ophthalmic Drugs,
U.S. Revenues and Share 2000-2010
- Figure 12-2: The World Market for Prescription Generic Ophthalmic Drugs
Displaying U.S. Revenues 2000-2010
- Table 12-5: The World Market for Prescription Generic Ophthalmic Drugs,
Revenues and Market Share by Supplier 2005
- Figure 12-3: The World Market for Prescription Generic Ophthalmic Drugs
Market Share by Leading Supplier 2005
Chapter Thirteen: World Market Summary
- Table 13-1: The World Market for Prescription Generic Drugs Revenues by
Segment 2000-2010
- Figure 13-1: The World Market for Prescription Generic Drugs Revenues by
Segment 2000-2010
- Figure 13-2: The World Market for Generic Drugs Market Share by Type
2005 and 2010
- Table 13-3: World Market for Prescription Generic Drugs Revenues and
Segments of Participation by Leading Player 2005
Chapter Fourteen: Issues and Trends
- Table 14-1: Reorganization of Major Japanese Generic Drug Manufacturers
|
 |
